Evidence map›Paper›PMID 25587296›Full record

ReviewThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale

Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective.

Michel Laverdiere, Eric J Bow, Coleman Rotstein, Julie Autmizguine, Raewyn Broady, Gary Garber, Shariq Haider, Trana Hussaini, Shahid Husain, Philippe Ovetchkine and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial.Transplant infectious disease : an official journal of the Transplantation Society · 2015
    Trial
  4. Article
  5. Evaluation of voriconazole therapeutic drug monitoring in malignant hematology patients.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2025
    Article
  6. Review
  7. Histoplasmosis in Solid Organ Transplantation.Journal of fungi (Basel, Switzerland) · 2024
    Review
  8. Review
  9. Article
  10. Article
  11. Pulmonary Histoplasmosis: A Clinical Update.Journal of fungi (Basel, Switzerland) · 2023
    Review
  12. Article
  13. Article
  14. Article
  15. Characterization of Therapeutic Drug Monitoring Practices of Voriconazole and Posaconazole at a Pediatric Hospital.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2021
    Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Michel LaverdiereDepartment of Microbiology and Infectious Diseases, Hôpital Maisonneuve-Rosemont, Montreal, Quebec;
Eric J BowDepartments of Medical Microbiology and Infectious Diseases, and Internal Medicine, Sections of Infectious Diseases and Hematology/Oncology, Blood and Marrow Transplant, University of Manitoba, Winnipeg, Manitoba;
Coleman RotsteinDivision of Infectious Diseases, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario;
Julie AutmizguineService des Maladies Infectieuses, Département de Pédiatrie; ; Unité de Pharmacologie Clinique, CHU Ste-Justine, Montreal, Quebec;
Raewyn BroadyDivision of Haematology, University of British Columbia, Vancouver, British Columbia;
Gary GarberDivision of Infectious Diseases, University of Ottawa/Ottawa Hospital, Ottawa;
Shariq HaiderHamilton Health Sciences, McMaster University, Hamilton, Ontario;
Trana HussainiSolid Organ Transplantation, Pharmaceutical Sciences Clinical Service Unit, Vancouver General Hospital, Vancouver, British Columbia;
Shahid HusainDivision of Infectious Diseases, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario;
Philippe OvetchkineService de Maladies Infectieuses, Département de Pédiatrie, CHU Sainte-Justine, Université de Montréal, Montreal, Quebec;
Jack T SekiDepartment of Pharmacy, Princess Margaret Cancer Centre, University Health Network; ; Leslie Dan Faculty of Pharmacy University of Toronto, Toronto, Ontario;
Yves ThéorêtUnité de Pharmacologie Clinique, CHU Ste-Justine, Montreal, Quebec; ; Département de Pharmacologie, Université de Montréal, Montreal, Quebec.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Invasive fungal infections cause significant morbidity and mortality in patients with concomitant underlying immunosuppressive diseases. The recent addition of new triazoles to the antifungal armamentarium has allowed for extended-spectrum activity and flexibility of administration. Over the years, clinical use has raised concerns about the degree of drug exposure following standard approved drug dosing, questioning the need for therapeutic drug monitoring (TDM). Accordingly, the present guidelines focus on TDM of triazole antifungal agents. A review of the rationale for triazole TDM, the targeted patient populations and available laboratory methods, as well as practical recommendations based on current evidence from an extended literature review are provided in the present document.

Indexed as

Invasive fungal infectionTherapeutic drug monitoringTriazole antifungal antibiotics

Identifiers

PMID25587296
PMCPMC4277162

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.